Survival by Number and Sites of Resections of Recurrence after First Curative Resection of Colorectal Liver Metastases.


Journal

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084

Informations de publication

Date de publication:
12 2022
Historique:
received: 17 05 2022
accepted: 06 08 2022
pubmed: 21 9 2022
medline: 23 11 2022
entrez: 20 9 2022
Statut: ppublish

Résumé

Recurrence after curative hepatectomy for colorectal liver metastases (CRLM) is common. We sought to determine if number and sites of resections of recurrence after hepatectomy for CRLM impact survival. The study included patients who underwent resection of recurrence following complete curative-intent resection of CRLM during 1998-2016 at two academic medical centers in Houston, USA, and Rome, Italy. The survival impacts of number and sites of resections of recurrence were evaluated. Patients with synchronous extrahepatic disease at curative CRLM resection were excluded. Among 2163 patients who underwent curative hepatectomy, 1456 (67.3%) developed a recurrence. Four hundred seventy-eight patients underwent one (322/478; 67.4%) or two or more (156/478; 32.6%) resections of recurrence. The 5-year overall survival (OS) rate was higher in patients with resected than unresected recurrence (70.2% vs. 24.0%; p < 0.001). In patients who underwent only one resection of recurrence, the 5-year OS rate differed by location (lung, 81.6%; liver, 64.3%; other, 54.1%). In patients who underwent two or more resections of recurrence, the 5-year OS rate was similar for liver-only resection (87.5%) and resection of liver and other sites (66.1%) (p = 0.223) and for liver-only resection and other-sites-only resection (80.7%) (p = 0.258); 5-year OS rate by site of first resection of recurrence did not differ between liver (78.5%) and lung (81.8%) (p = 0.502) but was worse for other sites (61.1%) than for lung (p = 0.045). When recurrence after initial CRLM resection is resectable, the ability to undergo resection was associated with improved survival and can be considered as an option regardless of the number of recurrence and resection. Sites of resection of recurrence impact survival and should be considered.

Sections du résumé

BACKGROUND
Recurrence after curative hepatectomy for colorectal liver metastases (CRLM) is common. We sought to determine if number and sites of resections of recurrence after hepatectomy for CRLM impact survival.
METHODS
The study included patients who underwent resection of recurrence following complete curative-intent resection of CRLM during 1998-2016 at two academic medical centers in Houston, USA, and Rome, Italy. The survival impacts of number and sites of resections of recurrence were evaluated. Patients with synchronous extrahepatic disease at curative CRLM resection were excluded.
RESULTS
Among 2163 patients who underwent curative hepatectomy, 1456 (67.3%) developed a recurrence. Four hundred seventy-eight patients underwent one (322/478; 67.4%) or two or more (156/478; 32.6%) resections of recurrence. The 5-year overall survival (OS) rate was higher in patients with resected than unresected recurrence (70.2% vs. 24.0%; p < 0.001). In patients who underwent only one resection of recurrence, the 5-year OS rate differed by location (lung, 81.6%; liver, 64.3%; other, 54.1%). In patients who underwent two or more resections of recurrence, the 5-year OS rate was similar for liver-only resection (87.5%) and resection of liver and other sites (66.1%) (p = 0.223) and for liver-only resection and other-sites-only resection (80.7%) (p = 0.258); 5-year OS rate by site of first resection of recurrence did not differ between liver (78.5%) and lung (81.8%) (p = 0.502) but was worse for other sites (61.1%) than for lung (p = 0.045).
CONCLUSION
When recurrence after initial CRLM resection is resectable, the ability to undergo resection was associated with improved survival and can be considered as an option regardless of the number of recurrence and resection. Sites of resection of recurrence impact survival and should be considered.

Identifiants

pubmed: 36127553
doi: 10.1007/s11605-022-05456-0
pii: 10.1007/s11605-022-05456-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2503-2511

Informations de copyright

© 2022. The Society for Surgery of the Alimentary Tract.

Références

de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Chota MA, Aldrighetti L, Capussotti L, Pawlik TM. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009;250:440-448.
doi: 10.1097/SLA.0b013e3181b4539b pubmed: 19730175
D’Angelica M, Kornprat P, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol 2011;18:1096-1103.
doi: 10.1245/s10434-010-1409-1 pubmed: 21042942
Beppu T, Sakamoto Y, Hasegawa K, Goro H, Kuniya T, Yoshihito K, Hiroyuki N, Hiroyuki Y, Etsuro H, Masaki U, Hiroyuki T, Hideo B, Tomoo K, Norihiro K, Keiichi T, Itaru E, Go W, Masaru M, Shinji U, Tetsuo O, Ken K, Hiroki Y, Masakazu Y, Tadahiro T. A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 2012;19:72-84.
doi: 10.1007/s00534-011-0460-z pubmed: 22020927
Saiura A, Yamamoto J, Hasegawa K, Koga R, Sakamoto Y, Hata S, Makuuchi M, Kokudo N. Liver resection for multiple colorectal liver metastases with surgery up-front approach: bi-institutional analysis of 736 consecutive cases. World J Surg 2012;36:2171-2178.
doi: 10.1007/s00268-012-1616-y pubmed: 22547015
Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013;258: 619-626.
doi: 10.1097/SLA.0b013e3182a5025a pubmed: 24018645
Shindoh J, Nishioka Y, Yoshioka R, Sugawara T, Sakamoto Y, Hasegawa K, Masaji H, Kokudo N. KRAS mutation status predicts site-specific recurrence and survival after resection of colorectal liver metastases irrespective of location of the primary lesion. Ann Surg Oncol 2016;23:1890-1896.
doi: 10.1245/s10434-016-5087-5 pubmed: 26786089
Vaillant JC, Balladur P, Nordlinger B, Karaitianos I, Hannoun L, Huguet C, Parc R. Repeat liver resection for recurrent colorectal metastases. Br J Surg 1993;80:340-344.
doi: 10.1002/bjs.1800800324 pubmed: 8472146
Petrowski H, Gonen M, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, Encke A, Blumgart L, Fong Y. Second liver resection are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002;235: 863-871.
doi: 10.1097/00000658-200206000-00015
Adam R, Pascal G, Azoulay D, Tanaka K, Castaing D, Bismuth H. Liver resection for colorectal metastases. The third hepatectomy. Ann Surg 2003;238:871-884.
pubmed: 14631224
Kulik U, Bektas H, Klempnauer J, Lehner F. Repeat liver resection for colorectal metastases. Br J Surg 2013;100:926-932.
doi: 10.1002/bjs.9132 pubmed: 23640669
Andreou A, Brouquet A, Abdalla EK, Aloia TA, Curley SA, Vauthey JN. Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate. HPB (Oxford) 2011;13:774-782.
doi: 10.1111/j.1477-2574.2011.00370.x pmcid: 3238011
Butte JM, Gonen M, Allen PJ, Kingham TP, Sofocleous CT, DeMatteo RP, Fong Y, Kemeny NE, Jarnagin WR, D'Angelica MI. Recurrence after partial hepatectomy for metastatic colorectal cancer: potentially curative role of salvage repeat resection. Ann Surg Oncol 2015;22:2761-2771.
doi: 10.1245/s10434-015-4370-1 pubmed: 25572686 pmcid: 4780326
Sponholz S, Schirren M, Baldes N, Oguzhan S, Schirren J. Repeat resection for recurrent pulmonary metastasis of colorectal cancer. Langenbecks Arch Surg 2017;402:77-85.
doi: 10.1007/s00423-016-1547-4 pubmed: 28058514
Hishida T, Tsuboi M, Okumura T, Boku N, Ohde Y, Sakao Y, Yoshiya K, Hyodo I, Mori K, Kondo H.
Yang KM, Park IJ, Lee JL, et al. Benefits of repeated resections for liver and lung metastases from colorectal cancer. Asian J Surg 2020;43:102-109.
doi: 10.1016/j.asjsur.2019.03.002 pubmed: 30910376
Nagakura S, Shirai Y, Suda T, et al. Multiple repeat resections of intrahepatic and extrahepatic recurrences in patients undergoing initial hepatectomy for colorectal carcinoma metastases. World J Surg 2002;26:141-147.
doi: 10.1007/s00268-001-0196-z pubmed: 11865339
Oba M, Hasegawa K, Shindoh J, et al. Survival benefit of repeat resection of successive recurrences after the initial hepatic resection for colorectal liver metastases. Surgery 2016;159:632-640.
doi: 10.1016/j.surg.2015.09.003 pubmed: 26477476
Imai K, Yamashita Y, Miyamoto Y, et al. The predictors and oncological outcomes of repeat surgery for recurrence after hepatectomy for colorectal liver metastases. Int J Clin Oncol 2018;23:908-916.
doi: 10.1007/s10147-018-1273-8 pubmed: 29619592
Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17:1225-1239.
doi: 10.1634/theoncologist.2012-0121 pubmed: 22962059 pmcid: 3481888
Viganò L, Costa G, Cimino MM, Procopio F, Donadon M, Del Fabbro F, Belghiti J, Kokudo N, Makuuchi M, Vauthey JN, Torzilli G. R1 resection for colorectal liver metastases: a survey questioning surgeons about its incidence, clinical impact, and management. J Gastrointest Surg 2018;22:1752-1763.
doi: 10.1007/s11605-018-3820-z pubmed: 29948554
Imai K, Allard MA, Benitez CC, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Bismuth H, Baba H, Adam R. Early recurrence after hepatectomy for colorectal liver metastases: what optimal definition and what predictive factors? Oncologist 2016;21:887-894.
doi: 10.1634/theoncologist.2015-0468 pubmed: 27125753 pmcid: 4943389
Matsumoto T, Hasegawa S, Hida K, Kawada K, Sakai Y, Sugihara K. Role of repeat resection in patients with metastatic colorectal cancer: a multicenter retrospective study. Dis Colon Rectum 2019;62:561-567.
doi: 10.1097/DCR.0000000000001311 pubmed: 30614848
Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Omichi K, Tzeng CD, Chun YS, Vauthey JN, Conrad C. RAS mutation is associated with unsalvageable recurrence following hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol 2018; 25:2457-2466.
doi: 10.1245/s10434-018-6517-3 pubmed: 29786130

Auteurs

Elena Panettieri (E)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA.
Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, 00168, Italy.

Bradford J Kim (BJ)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA.

Yoshikuni Kawaguchi (Y)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA.

Francesco Ardito (F)

Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, 00168, Italy.

Caterina Mele (C)

Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, 00168, Italy.

Agostino Maria De Rose (AM)

Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, 00168, Italy.

Maria Vellone (M)

Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, 00168, Italy.

Yun Shin Chun (YS)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA.

Ching-Wei D Tzeng (CD)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA.

Thomas A Aloia (TA)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA.

Felice Giuliante (F)

Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, 00168, Italy.

Jean-Nicolas Vauthey (JN)

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA. jvauthey@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH